Alzamend Neuro, Inc.
ALZN · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Market Cap | $2,678 | $216,286 | $2,330,933 | $4,082,805 |
| - Cash | $3,949 | $376 | $5,141 | $14,064 |
| + Debt | $0 | $301 | $0 | $0 |
| Enterprise Value | -$1,271 | $216,211 | $2,325,792 | $4,068,741 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$51 | -$51 | -$23 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$4,446 | -$9,887 | -$14,847 | -$12,316 |
| % Margin | – | – | – | – |
| Net Income | -$4,515 | -$9,948 | -$14,878 | -$12,362 |
| % Margin | – | – | – | – |
| EPS Diluted | -11.32 | -14.7 | -2.25 | -2.1 |
| % Growth | 23% | -553.3% | -7.1% | – |
| Operating Cash Flow | -$6,568 | -$8,270 | -$8,923 | -$6,614 |
| Capital Expenditures | -$300 | -$147 | $0 | -$106 |
| Free Cash Flow | -$6,868 | -$8,417 | -$8,923 | -$6,720 |